Inhibition of immune complex formation

Details Inhibition of immune complex formation Inhibition of immune complex formation

2005-07-12

2005-07-12

Borin, Michael (Department: 1631)

Chemistry: natural resins or derivatives; peptides or proteins;

Peptides of 3 to 100 amino acid residues

11 to 14 amino acid residues in defined sequence

C530S300000, C514S002600, C514S014800

Reexamination Certificate

active

06916904

ABSTRACT:
Polypeptides and other compounds that can bind specifically to the CH2-CH3 cleft of an immunoglobulin molecule, and methods for using such polypeptides and compounds to inhibit Fc-mediated immune complex formation, are described.

REFERENCES:
patent: 5189014 (1993-02-01), Cowan, Jr.
patent: 6319897 (2001-11-01), Lambris et al.
patent: 0 097 994 (1987-09-01), None
patent: 0 098 829 (1989-05-01), None
patent: WO 98/26794 (1998-06-01), None
patent: WO 00/22112 (2000-04-01), None
patent: WO 01/45746 (2001-06-01), None
patent: WO 02/38592 (2002-05-01), None
Abdul-Majid et al., “Fc Receptors are Critical for Autoimmune Inflammatory Damage to the Central Nervous System in Experimental Autoimmune Encephalomyelitis,”Scand. J. Immunol.,2002, 55:70-81.
Åsbakk et al., “An antigenic determinant is shared by psoriasis-associated p27 antigen and the Fc part of human IgG,”APMIS,1991, 99:551-556.
Artandi et al., “Monoclonal Igm rheumatoid factors bind IgG at a discontinuous epitope comprised of amino acid loops from heavy-chain constant-region domains 2 and 3,”Proc. Natl. Acad. Sci., USA,1992, 89:94-98.
Balestrieri et al. “Inhibitory Effect of IgM Rheumatoid Factor on Immune Complex Solubilization Capacity and Inhibition of Immune Precipitation,”Arthritis Rheum.,1984, 27(10):1130-1136.
Blom et al., “FcγR expression on macrophages is related to severity and chronicity of synovial inflammation and cartilage destruction during experimental immune-complex-mediated arthritis (ICA),”Arthritis Res.,2000, 2:489-503.
Bonelli et al., “Solid phase synthesis of retro-inverso peptide analogues,”Int. J. Peptide Protein Res.,1984, 24:553-556.
Chen et al., “Experimental Destruction of Substantia Nigra Initiated by Parkinson Disease Immunoglobulins,”Arch. Neurol.,1998, 55:1075-1080.
Clot et al., “Immunological aspects of psoriasis,”Br. J. Dermatol.,1978, 99:25-30.
Clynes et al., “Fc receptors are required in passive and active immunity to melanoma,”Proc. Natl. Acad. Sci. USA,1998, 95:652-656.
Clynes et al., “Uncoupling of Immune Complex Formation and Kidney Damage in Autoimmune Glomerulonephritis,”Science,1998, 279:1052-1054.
Clynes et al., “Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets,”Nature Medicine;2000, 6(4):443-446.
Corper et al., “Structure of human IgM rheumatoid factor Fab bound to its autoantigen IgG Fc reveals a novel topology of antibody-antigen interaction,”Nat. Struct. Biol.,1997, 4(5):374-381.
Costa et al., “Non-Specific Binding of Heat-Aggregated IgG to Histone Detected by ELISA,”J. Immunol. Methods,1984, 74:283-291.
Coxon et al., “FcγRIII Mediates Neutrophil Recruitment to Immune Complexes: A Mechanism for Neutrophil Accumulation in Immune-Mediated Inflammation,”Immunity,2001, 14:693-704.
Coyle, and Procyk-Dougherty, “Multiple Sclerosis Immune Complexes: An Analysis of Component Antigens and Antibodies,”Ann. Neurol.,1984, 1:660-667.
Dalaker et al., “Expression of the Psoriasis-associated Antigen, Pso p27, in Inhibited by Cyclosporin A,”Acta Derm. Venereol.,1999, 79:281-284.
DeLano et al., “Convergent Solutions to Binding at a Protein-Protein Interface,”Science,2000, 287:1279-1283.
Easterbrook-Smith et al., “The Role of Fc:Fc Interactions in Insoluble Immune Complex Formation and Complement Activation,”Mol. Immunol.,1988, 25(12):1331-1337.
Elmgreen et al., “Demonstration of Circulating Immune Complexes by the Indirect Leucocyte Phagocytosis Test in Chronic Inflammatory Bowel Disease,”Acta Med. Scand.,1985, 218:73-78.
Ezaki et al., “Human monoclonal rheumatoid factors augment arthritis in mice by the activation of T cells,”Clin. Exp. Immunol.,1996, 104:474-482.
Fossati et al., “Fcγ receptors in autoimmune diseases,”Eur. J. Clin. Invest.,2001, 31:821-831.
Frangione and Milstein, “Variations in the S-S Bridges of Immunoglobins G: Interchain Disulphide Bridges of γG3 Myeloma Proteins,”J. Mol. Biol.,1968, 33:893-906.
Gergely and Sármay, “Fcγ Receptors in Malignancies: Friends or Enemies?”Adv. Cancer Res.,1994, 64:211-245.
Ghetie and Ward, “Multiple Roles for the Major Histocompatibility Complex Class I-Related Receptor FCRN,”Annu. Rev. Immunol.,2000, 18:739-766.
Girkontaite et al., “Immunochemical Study of Human Immunoglobulin G Fc Region,”Cancer Biother. Radiopharm.,1996, 11:87-96.
Glader et al., “The proatherogenic properties of lipoprotein(a) may be enhanced through the formation of circulating immune complexes containingChlamydia pneumoniae-specific IgG antibodies,”Eur. Heart J.,2000, 21:639-646.
Gómez-Guerrero et al., “Administeration of IgG Fc Fragments Prevents Glomerular Injury in Experimental Immune Complex Nephritis,”J. Immunol.,2000, 164:2092-2101.
Guddat et al., “Local and Transmitted Conformational Changes on Complexation of an Anti-sweetener Fab,”J. Mol. Biol.,1994, 236:247-274.
Gussin et al., “Noncognate Binding to Histones of IgG from Patients with Idiopathic Systemic Lupus Erythematosus,”Clin. Immunol.,2000, 96(2):150-161.
Hamano et al., “Immune Complex and Fc Receptor-Mediated Augmentation of Antigen Presentation for in Vivo Th Cell Responses,”J. Immunol.,2000, 164:6113-6119.
Harris et al., “Refined Structure of an Intact IgG2a Monoclonal Antibody,”Biochemistry,1997, 36:1581-1597.
Holmdahl et al., “Generation of Monoclonal Rheumatoid Factors after Immunization with Collagen II- Anti-Collagen II Immune Complexes,”Scand. J. Immunol.,1986, 24:197-203.
Hoover et al., “Modulation of Growth and Differentiation of Murine Myeloma Cells by Immunoglobulin Binding Factors,”Curr. Top. Microbiol. Immunol.,1990, 166:77-85.
Iivanainen, “The significance of abnormal immune responses in patients with multiple sclerosis,”J. Neuroimmunol.,1981, 1:141-172.
Jackson, “Contributions of Protein Structure-Based Drug Design to Cancer Chemotherapy,”Sem. Oncol.,1997, 24(2):164-172.
Jefferis et al., “Immunogenic and Antigenic Epitopes of Immunoglobulins. VIII. A Human Monoclonal Rheumatoid Factor Having Specificity for a Discontinuous Epitope Determined by Histidine/Arginine Interchange as Residue 435 of Immunoglobulin G,”Immunol. Lett.,1984, 7:191-194.
Jones et al., “Structure-Based Design of Lipophilic Quinazoline Inhibitors of Thymidylate Synthase,”J. Med. Chem.,1996, 39:904-917.
Kabat et al.,Sequences of Proteins of Immunological Interest,Fourth Edition, 1987, U.S. Department of Health and Human Services, Public Health Service National Institutes of Health, 1987, (Table of Contents only).
Kleinau et al., “Induction and Suppression of Collagen-induced Arthritis Is Dependent on Distinct Fcγ Receptors,”J. Exp. Med.,2000, 191(9):1611-1616.
Koroleva et al., “Binding of complement subcomponent C1q toStreptococcus pyogenes:evidence for interactions with the M5 and FcRA76 proteins,”FEMS Immunol. Med. Microbiol.,1998, 20:11-20.
Leach et al., “Isolation from Human Placenta of the IgG Transporter, FcRn, and Localization to the Syncytiotrophoblast,”J. Immunol.,1996, 157:3317-3322.
Liu et al., “β2-microglobulin-deficient Mice Are Resistant to Bullous Pemphigoid,”J. Exp. Med.,1997, 186(5):777-783.
Manzi et al., “Inflammation-mediated rheumatic diseases and atherosclerosis,”Ann. Rheum. Dis.,2000, 59(5):321-325.
Marino et al., “Prevention of systemic lupus erythematosus in MRL/lpr mice by administration of an immunoglobulin-binding peptide,”Nature Biotechnol.,2000, 18:735-739.
Mathiot et al., “In vitro Inhibition of Tumor B Cell Growth by IgG-BF-Producing FcγRII+ T Cell Hybridoma and by Immunoglobulin G-Binding Factors,”Immun

Affiliated with

Also associated with

Rating

Inhibition of immune complex formation does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Inhibition of immune complex formation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibition of immune complex formation will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3409754